MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1176/appi.ajp.162.7.1281

Медицинская библиотека · The American journal of psychiatry · 2005

Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.

Tohen Mauricio, Greil Waldemar, Calabrese Joseph R, Sachs Gary S, Yatham Lakshmi N, Oerlinghausen Bruno Müller, Koukopoulos Athanasios, Cassano Giovanni B, Grunze Heinz, Licht Rasmus W, Dell'Osso Liliana, Evans Angela R, Risser Richard, Baker Robert W, Crane Heidi, Dossenbach Martin R, Bowden Charles L

Клиническое исследованиеСравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

The authors compared the efficacy of olanzapine and lithium in the prevention of mood episode relapse/recurrence.

METHOD: Patients with a diagnosis of bipolar disorder (manic/mixed), a history of two or more manic or mixed episodes within 6 years, and a Young Mania Rating Scale total score > or =20 entered the study and received open-label co-treatment with olanzapine and lithium for 6-12 weeks. Those meeting symptomatic remission criteria (Young Mania Rating Scale score < or =12; 21-item Hamilton depression scale score < or =8) were randomly assigned to 52 weeks of double-blind monotherapy with olanzapine, 5-20 mg/day (N=217), or lithium (target blood level: 0.6-1.2 meq/liter) (N=214).

RESULTS

Symptomatic relapse/recurrence (score > or =15 on either the Young Mania Rating Scale or Hamilton depression scale) occurred in 30.0% of olanzapine-treated and 38.8% of lithium-treated patients. The noninferiority of olanzapine relative to lithium (primary objective) in preventing relapse/recurrence was met, since the lower limit of the 95% confidence interval on the 8.8% risk difference (-0.1% to 17.8%) exceeded the predefined noninferiority margin (-7.3%). Secondary results showed that compared with lithium, olanzapine had significantly lower risks of manic episode and mixed episode relapse/recurrence. Depression relapse/recurrence occurred in 15.7% of olanzapine-treated and 10.7% of lithium-treated patients. Mean weight gain during open-label co-treatment was 2.7 kg; during double-blind monotherapy, weight gain was significantly greater with olanzapine (1.8 kg) than with lithium (-1.4 kg).

CONCLUSIONS

These results suggest that olanzapine was significantly more effective than lithium in preventing manic and mixed episode relapse/recurrence in patients acutely stabilized with olanzapine and lithium co-treatment. Both agents were comparable in preventing depression relapse/recurrence.

Для цитирования: Tohen Mauricio, Greil Waldemar, Calabrese Joseph R, Sachs Gary S, Yatham Lakshmi N, Oerlinghausen Bruno Müller, Koukopoulos Athanasios, Cassano Giovanni B, Grunze Heinz, Licht Rasmus W, Dell'Osso Liliana, Evans Angela R, Risser Richard, Baker Robert W, Crane Heidi, Dossenbach Martin R, Bowden Charles L. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.. The American journal of psychiatry. 2005. DOI: 10.1176/appi.ajp.162.7.1281.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.